Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0016632 (
Fox
)
1,461
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The addition of phosphate groups to substrates allows protein kinases to regulate a myriad of biological processes, and contextual analysis of protein-bound phosphate is important for understanding how kinases contribute to physiology and disease.
Leucine-rich repeat kinase 2
(
LRRK2
) is a Ser/Thr kinase linked to familial and sporadic cases of Parkinson's disease (PD). Recent work established that multiple Rab GTPases are physiological substrates of
LRRK2
, with Rab10 in particular emerging as a human substrate whose site-specific phosphorylation mirrors hyperactive
LRRK2
lesions associated with PD. However, current assays to quantify Rab10 phosphorylation are expensive, time-consuming and technically challenging. In back-to-back studies reported in the
Biochemical Journal
, Alessi and colleagues teamed up with clinical colleagues and collaborators at the Michael J.
Fox
Foundation (MJFF) for Parkinson's research to develop, and validate, a panel of exquisitely sensitive phospho-specific Rab antibodies. Of particular interest, the monoclonal antibody-designated MJFF-pRAB10 detects phosphorylated Rab 10 on Thr73 in a variety of cells, brain extracts, PD-derived samples and human neutrophils, the latter representing a previously unrecognised biological resource for
LRRK2
signalling analysis. In the future, these antibodies could become universal resources in the fight to understand and quantify connections between
LRRK2
and Rab proteins, including those associated with clinical PD.
...
PMID:Back to the future: new target-validated Rab antibodies for evaluating LRRK2 signalling in cell biology and Parkinson's disease. 2912 56